Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-01-17, Stock:NVO, The news for the past five days is as follows:
2018-01-09: NEWS1: Novo Nordisk Confirms Bid for Ablynx But Faces Rejection.NEWS2: Ozempic® approved in Canada for the treatment of adults with type 2 diabetes.NEWS3: Ozempic® approved in Canada for the treatment of adults with type 2 diabetes.NEWS4: [$$] Belgium’s Ablynx Rejects Novo Nordisk Bid.
2018-01-10: NEWS1: Eli Lilly & Co. at J.P. Morgan: 5 Things Investors Will Want to Know.NEWS2: Eli Lilly & Co. at J.P. Morgan: 5 Things Investors Will Want to Know.NEWS3: Novo Nordisk's Ozempic Gets Canadian Approval for Diabetes.NEWS4: Novo Nordisk&apos;s Ozempic Gets Canadian Approval for Diabetes.
2018-01-11: NEWS1: Why is Novo Nordisk Stock Up More Than 50% in Past Year?.NEWS2: Why is Novo Nordisk Stock Up More Than 50% in Past Year?.NEWS3: How Is Bioverativ’s Eloctate Positioned Now?.NEWS4: How Is Roche’s Hemlibra Positioned for 2018?.
2018-01-12: NEWS1: Three Diabetes Clinical Trials to Watch in 2018.NEWS2: Pharma Stock Roundup: Novo Nordisk Reveals Bid to Acquire Ablynx, Pfizer & Others at Healthcare Conference.NEWS3: Pharma Stock Roundup: Novo Nordisk Reveals Bid to Acquire Ablynx, Pfizer & Others at Healthcare Conference.
2018-01-16: NEWS1: Teva's Trisenox Gets FDA Approval as First-Line Treatment.NEWS2: Eli Lilly's Risks Could Be Underappreciated, Goldman Sachs Says In Downgrade.NEWS3: The Race To Find A Treatment For NASH.NEWS4: The Race To Find A Treatment For NASH.

Answer: Rise